In November 2022, the FDA approved tremelimumab plus durvalumab and platinum-based chemotherapy for patients with metastatic non–small cell lung cancer who have an EGFR mutation or ALK alteration.
FDA Approves Tremelimumab Plus Durvalumab for Advanced NSCLC
The FDA has approved tremelimumab plus durvalumab for patients with metastatic non–small cell lung cancer based on findings from arms 1 and 3 of the phase 3 POSEIDON trial.
Melissa L. Johnson, MD, on the Approval of Tremelimumab Plus Durvalumab/Chemo in NSCLC
Melissa L. Johnson, MD, spoke about the design of the phase 3 POSEIDON trial how its data led to the recent approval of tremelimumab plus durvalumab and chemotherapy in patients with advanced non–small cell lung cancer.
2 Clarke Drive Cranbury, NJ 08512